4-(4-Nitro-phenylsulfonyl)-triazol | 14544-44-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-Nitro-phenylsulfonyl)-triazol
• 英文别名: 4-(4-nitro-benzenesulfonyl)-1H-[1,2,3]triazole；4-(4-nitrophenyl)sulfonyl-2H-triazole
• CAS: 14544-44-6
• 化学式: C₈H₆N₄O₄S
• 分子量: 254.226
• InChiKey: KLYHOCCIJZVGMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  130
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Diphosphines, preparation and uses thereof
  申请人：Lemaire Marc

  公开号：US20070010695A1

  公开（公告）日：2007-01-11

  The invention concerns novel diphosphines of formula (I) useful in particular, in their optically active form, as ligands in metal complexes. The invention also concerns their uses an intermediates in the preparation of polymeric insoluble ligands. The invention further concerns the use of said insoluble ligands in the preparation of metal complexes for asymmetric. catalysis.

  该发明涉及公式（I）的新型二膦化合物，特别是它们的光学活性形式，在金属配合物中作为配体的有用性。该发明还涉及它们作为聚合物不溶性配体的中间体在制备中的用途。此外，该发明还涉及所述不溶性配体在制备用于不对称催化的金属配合物中的应用。
• Ether type lipid a 1-carboxylic acid analogs
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20020161221A1

  公开（公告）日：2002-10-31

  A compound of formula (I) below, which exhibits excellent macrophage activity inhibitory action, is useful for the treatment or prophylaxis of inflammatory disorders, autoimmune diseases or septicemia. In a preferred embodiment, R 1 and R 3 each represents a C 1 -C 20 alkanoyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R 2 and R 4 each represents a C 1 -C 20 alkyl group which may optionally be substituted with one or more substituent groups selected from substituent group A, R 5 is a hydrogen atom, a halogen atom, a hydroxy group, or a C 1 -C 6 alkoxy group, and substituent group A is a halogen atom, a hydroxy group, an oxo group, a C 1 -C 20 alkoxy group, or a C 1 -C 20 alkanoyloxy group. 1

  以下为化合物式（I），该化合物表现出出色的巨噬细胞活性抑制作用，可用于治疗或预防炎症性疾病、自身免疫性疾病或败血症。在首选实施例中，R1和R3各代表一个C1-C20烷酰基团，该基团可以选择性地被一个或多个取代基团A所取代，R2和R4各代表一个C1-C20烷基团，该基团可以选择性地被一个或多个取代基团A所取代，R5是氢原子、卤素原子、羟基或C1-C6烷氧基团，取代基团A是卤素原子、羟基、氧代基、C1-C20烷氧基团或C1-C20烷酰氧基团。
• NEURAMINIC ACID COMPOUNDS
  申请人：Sankyo Company, Limited

  公开号：EP0934939A1

  公开（公告）日：1999-08-11

  [Constitution] A neuraminic acid compound represented by the formula: [wherein R1 represents a C1-C4 group which may be substituted with a halogen atom; R2, R3 and R4 may be the same or different and each represents a hydrogen atom or a C3-C25 aliphatic acyl group; and W represents a hydrogen atom or an ester residue, provided that the case where R1 is a methyl group and each of R2, R3, R4 and W is a hydrogen atom is excluded] or a pharmacologically acceptable salt thereof. [Effect] The neuraminic acid compound of the present invention exhibits excellent in vivo sialidase inhibitory activity and is useful as a therapeutic agent or a preventive agent for influenza viral infections.

  [组织结构］ 一种由式表示的神经氨酸化合物： [其中 R1 代表可被卤素原子取代的 C1-C4 基团；R2、R3 和 R4 可以相同或不同，且各自代表氢原子或 C3-C25 脂肪酰基；W 代表氢原子或酯残基，但不包括 R1 为甲基且 R2、R3、R4 和 W 中各自为氢原子的情况。］ 或其药理上可接受的盐。 效果 本发明的神经氨酸化合物具有优异的体内苷脂酶抑制活性，可用作流感病毒感染的治疗剂或预防剂。
• ALICYCLIC ACYLATED HETEROCYCLIC DERIVATIVES
  申请人：Sankyo Company Limited

  公开号：EP1048658A1

  公开（公告）日：2000-11-02

  Compounds represented by general formula (1) and having a selective antagonism to NK2 receptors and pharmacologically acceptable salts or derivatives thereof wherein R1 represents optionally substituted cycloalkyl or an optionally substituted saturated heterocycle; R2 represents aryl, etc.; A represents methylene, etc.; B represents a single bond, alkylene, etc.; D represents oxygen or sulfur; G represents alkylene, etc.; L represents -N(R3)- or -C(R4)(R5)- [wherein R3 represents aryl, etc.; R4 represents aryl, etc.; and R5 represents optionally aminated alkyl or -CO-R6 (wherein R6 represents alkyl, etc.); or R4 and R5 may form together a cycloalkane ring, etc.]; R7 represents alkyl; Z represents two hydrogen atoms or an oxygen atom; and n is 0, 1 or 2.

  通式(1)代表的对 NK2 受体有选择性拮抗作用的化合物及其药理上可接受的盐或衍生物 其中 R1 代表任选取代的环烷基或任选取代的饱和杂环；R2 代表芳基等；A 代表亚甲基等；B 代表单键、亚烷基等；D 代表氧或硫；G 代表亚烷基等；L 代表-N(R3)-或-C(R4)(R5)-[其中 R3 代表芳基等；C(R4)(R5)-代表烷基等]。L 代表-N(R3)-或-C(R4)(R5)-[其中 R3 代表芳基等；R4 代表芳基等；R5 代表任选胺化烷基或-CO-R6（其中 R6 代表烷基等）；或 R4 和 R5 可共同形成环烷环等]；R7 代表烷基；Z 代表两个氢原子或一个氧原子；n 为 0、1 或 2。
• SULFONAMIDE DERIVATIVES
  申请人：Sankyo Company Limited

  公开号：EP1069110A1

  公开（公告）日：2001-01-17

  [Object] The object is to provide a compound having matrixmetalloproteinase-13 inhibitory activity and aglycanase inhibitory activity. [Solution] A compound of the following formula (I) or a pharmacologically acceptable salt, ester or other derivative thereof: R1: H, NHOH; R2: H, optionally substituted alkyl, cycloalkyl, a group -AR6 [A: an alkylene which may be optionally interrupted by O, -S(O)m- or -N(R9); R6: a group (II), (III), (IV) X: O, S, -N(R10)-, -C(R11)(R12)-; Y: O, CO, -S(O)n-, -N(R10)-, -C(R11)(R12)-; R7, R8: H, alkyl, COOH, optionally subsituted alkyl, etc.; R9, R10, R11, R12: H, alkyl, etc.; m, n: 0 to 2] R3: H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, optionally substituted alkynyl; R4: optionally substituted (hetero)arylene; R5: optionally substituted alkyl, optionally substituted (hetero)aryl}.

  目的 目的是提供一种具有基质金属蛋白酶-13 抑制活性和琼脂糖酶抑制活性的化合物。 [解决方案］ 下式(I)的化合物或其药理学上可接受的盐、酯或其他衍生物： R1: H, NHOH; R2：H、任选取代的烷基、环烷基、基团 -AR6 [A：可任选被 O、-S(O)m- 或 -N(R9)打断的亚烷基；R6：基团 (II)、(III)、(IV) X：O、S、-N(R10)-、-C(R11)(R12)-； Y：O、CO、-S(O)n-、-N(R10)-、-C(R11)(R12)-； R7、R8：H、烷基、COOH、任选亚烷基等； R9、R10、R11、 R9、R10、R11、R12：H、烷基等； m、n：0 至 2］ R3：H、任选取代的烷基、任选取代的环烷基、任选取代的烯基、任选取代的炔基；R4：任选取代的（杂）芳基；R5：任选取代的烷基、任选取代的（杂）芳基}。